Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Superinvestors holding ALLO, Q2 2026
No superinvestor reported holding ALLO in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ALLO each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- HHLR Advisors (Hillhouse)
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−22.1%)